Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
--Lilly/BI non-insulin diabetes drug hits efficacy goals in clinical studies
--Companies plan to submit drug, empagliflozin, for regulatory approval this year
--Companies end collaboration on an experimental insulin drug
A non-insulin diabetes drug co-developed by Boehringer Ingelheim GmbH and Eli Lilly & Co. ( LLY ) reduced blood-sugar levels compared with a placebo in four clinical trials, the companies said Monday.
The companies also said they modified a two-year-old diabetes partnership, with Boehringer Ingelheim terminating its participation in the development of another drug, an experimental form of insulin. Lilly will reassume full rights to the insulin product, while the companies will continue to collaborate on other drugs.
http://www.nasdaq.com/article/lilly...ends-insulin-pact-20130107-01032#.UOsbbG_sySo
--Companies plan to submit drug, empagliflozin, for regulatory approval this year
--Companies end collaboration on an experimental insulin drug
A non-insulin diabetes drug co-developed by Boehringer Ingelheim GmbH and Eli Lilly & Co. ( LLY ) reduced blood-sugar levels compared with a placebo in four clinical trials, the companies said Monday.
The companies also said they modified a two-year-old diabetes partnership, with Boehringer Ingelheim terminating its participation in the development of another drug, an experimental form of insulin. Lilly will reassume full rights to the insulin product, while the companies will continue to collaborate on other drugs.
http://www.nasdaq.com/article/lilly...ends-insulin-pact-20130107-01032#.UOsbbG_sySo